Ascendis Pharma Lifts Operating Margin To 34% From 5% As YORVIPATH Sales Grow

Product revenue rose 89% as international launches expanded the reach of its hormone replacement treatment.

Share
Ascendis Pharma Lifts Operating Margin To 34% From 5% As YORVIPATH Sales Grow

Ascendis Pharma, which develops and sells medicines for rare hormone disorders, reported a third-quarter operating margin of 34%, versus 5% a year earlier in its Thursday earnings release. Operating profit reached €125 million from €11 million, an increase it attributed mainly to YORVIPATH sales growth, with global expansion costs offsetting part of the gain.

YORVIPATH pays for expanding reach

Product revenue rose 89% to €366 million. YORVIPATH contributed €291 million, up 103%, while SKYTROFA generated €59 million and YUVIWEL brought in €16 million. Including other revenue, sales reached €370 million from €214 million a year earlier.

Ascendis said new YORVIPATH patient demand accelerated outside the United States as it launched in additional markets. U.S. demand was consistent with previous quarters. The medicine is available in more than 40 countries through commercial sales or programs supplying named patients.

YORVIPATH replaces a hormone in adults with hypoparathyroidism; SKYTROFA treats growth hormone deficiency in children and adults. Both use Ascendis's TransCon technology, which releases active drugs over time. The company sells through U.S. commercial teams and specialty pharmacies, directly in selected European countries and through partners elsewhere.

Selling, general and administrative costs reached €147 million from €113 million, which Ascendis attributed primarily to commercial expansion and launches. Research and development spending rose to €70 million from €67 million as increased rare-endocrine-disease trial activity partly outweighed reduced oncology trial activity. Total operating expenses reached €217 million from €180 million.

Net profit was €74 million, or €1.08 per diluted ordinary share, against a €61 million loss a year earlier. Net finance expenses fell to €4 million from €61 million; Ascendis said non-cash items accounted for most of that change. Its adjusted operating profit reached €156 million from €42 million, excluding share-based pay costs.

Cash generation supports share repurchases

Ascendis generated €189 million in operating cash flow during the quarter and expects at least €600 million for full-year 2026.

For the first nine months, operating cash flow reached €463 million, compared with €20 million used a year earlier. Ascendis attributed the improvement mainly to commercial revenue growth and €158 million in net proceeds from selling a priority review voucher. Less favorable working-capital changes of approximately €15 million, along with higher interest and tax payments, partly offset those gains.

The commercial business has grown substantially from the first nine months of 2025, when product sales totaled about €443 million. Selling, general and administrative expenses of about €322 million and research spending of about €225 million contributed to an operating loss of about €146 million for that period.

Cash holdings stood at €964 million on September 30, versus €616 million on December 31, 2025. Through November 11, Ascendis had repurchased 1,998,999 ordinary shares for $459 million, compared with 794,304 shares for $186 million through September 30.

YUVIWEL heads toward European decision

European medicines committees recommended marketing authorization for TransCon CNP to treat children with achondroplasia and maintenance of its orphan-medicine designation. Ascendis expects a European Commission decision in the fourth quarter of 2026 and plans its first European Union launch in Germany in the first quarter of 2027.

In the United States, YUVIWEL had approximately 340 unique patient enrollments from nearly 150 prescribing healthcare providers through October 31. More than 80% of enrollments had reimbursement approval. Ascendis expects revenue from multiple countries outside the United States and European Union in the coming quarters through early-access programs.

The company presented 52-week infant cohort results showing that TransCon CNP stabilized or improved skull narrowing that can compress the brain stem and spinal cord, alongside linear growth benefits. The infants had achondroplasia and were younger than two years; pivotal results are expected in the third quarter of 2027.

Ascendis also expects to begin enrolling children with hypochondroplasia in a late-stage trial and start a mid-stage achondroplasia trial in adults in the fourth quarter of 2026. A late-stage study combining TransCon CNP with TransCon hGH in children with achondroplasia is underway, with enrollment completion expected in the second quarter of 2027.

The planned German launch would extend Ascendis's commercial growth strategy to another treatment for children with growth disorders, pending the European Commission's decision.

Sources